Skye Bioscience, Inc. (SKYE): Cash & Equivalents
$5.88M
As of 2025-12-31
$8.07M
As of 2026-06-30
+6.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.88M | -91.4% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $68.42M | n/m | 2026-03-10, Balance as of period end |
| 2023-12-31 | $1.26M | n/a | 2025-03-20, Balance as of period end |
| No annual figure between 2018-12-31 and 2023-12-31. | |||
| 2018-12-31 | $1.85M | +613.0% | 2019-03-14, Balance as of period end |
| 2017-12-31 | $260.0K | +301.0% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $64.8K | -98.0% | 2018-03-19, Balance as of period end |
| 2015-12-31 | $3.22M | n/m | 2017-03-10, Balance as of period end |
| 2014-12-31 | $207.3K | n/a | 2016-03-21, Balance as of period end |
| No annual figure between 2013-10-31 and 2014-12-31. | |||
| 2013-10-31 | $52.2K | +97.6% | 2014-01-27, Balance as of period end |
| 2012-10-31 | $26.4K | n/a | 2014-01-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $5.88M | -91.4% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $6.39M | +8.2% |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | $19.87M | +39.8% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $3.62M | -71.4% |
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $21.62M | +148.1% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $5.89M | -33.5% |
| Veru Inc. (VERU) | 2025-09-30 | $15.79M | -36.6% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $24.03M | +20.6% |
Compare SKYE, BFRI, NEUP, HURA side by side · Screen every company in Pharmaceutical Preparations ↗